Related Experiment Videos
Nuclear factor-kappaB and liver carcinogenesis
Marcello Arsura1, Lakita G Cavin
1Department of Pharmacology, College of Medicine, University of Tennessee Cancer Institute, University of Tennessee Health Science Center, 874 Union Avenue, Memphis, TN 38163, USA. marsura@utmem.edu
Cancer Letters
|August 30, 2005
Summary
Hepatocellular carcinoma (HCC), a deadly liver cancer, is linked to NF-kappaB activation. Inhibiting NF-kappaB may offer a targeted treatment for malignant liver cells.
Area of Science:
- Hepatology
- Oncology
- Molecular Biology
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally.
- Hepatitis B/C virus infections, alcohol, and aflatoxin B1 are key risk factors for HCC.
- Rising HCV incidence in the US predicts a future HCC health crisis.
Purpose of the Study:
- To understand molecular events in hepatocarcinogenesis.
- To identify novel therapeutic targets for HCC.
- To investigate the role of NF-kappaB in liver cancer development.
Main Methods:
- Review of recent laboratory findings.
- Analysis of studies implicating NF-kappaB in liver neoplastic progression.
- Evaluation of NF-kappaB's role in linking growth factors and inflammation to oncogenesis.
Main Results:
- Constitutive activation of NF-kappaB is an early event in liver cancer.
- NF-kappaB plays a critical role in hepatocarcinogenesis.
- NF-kappaB bridges growth factor and inflammatory signals to liver oncogenesis.
Conclusions:
- NF-kappaB is a key factor in liver cancer development.
- Pharmacologic inhibition of NF-kappaB could selectively target malignant liver cells.
- Targeting NF-kappaB may offer a novel therapeutic strategy for HCC without disrupting normal liver function.